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Research Question
Could genes involved in endothelial cell adhesion, 
like VCAM1,  act as modulators in the onset and 
severity of vasculopathy, namely pediatric CVA?
Background
 Sickle cell anemia (SCA) – chronic vascular disease caused by homozygous 
c.20A>T mutation  in the HBB gene, resulting in abnormal hemoglobin S  
(HbS) accumulation in erythrocytes;
 Pediatric subphenotypes include cerebral vasculopathy (CVA), pain 
crisis, frequent infections and  renal disease;
 Genetic modulation has been described to affect pathophysiology of SCA.
Take home messages
 Functional studies show increased VCAM1 expression on cytokine-induced endothelial cells ;
 Promoter haplotypes,  previously associated with CVA, show different effects and confirm VCAM1  modulation of endothelial cell response;
 The results on different endothelial cell models enhance the possibility of this effect extending beyond cerebral to systemic vasculopathy.
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Recent Results
 Basal VCAM1 promoter activity is affected by all VCAM1 haplotypes tested, both 
in micro and macrovascular endothelial cells (Fig.1, left);
 Stimulation with TNF-α leads to a 2-fold increase in promoter activity in cells
transfected with haplotypes 4 or 7, when compared with non-stimulated cells;
 In a pro-inflammatory milieu, haplotype 1 leads to a less active VCAM1
promoter in brain microvascular cells, suggestive of a protective effect;
 The presence of haplotype 7 results the highest promoter activity, especially in 
brain microvascular cells (Fig. 1, right);
 The inductive effect of haplotype 4 is more significant in macrovascular cells, 
despite 2-fold increase, in stimulated cells. 
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Figure 1. VCAM1 Promoter activity ratios, as measured by luciferase assay. normalised to empty vector
construct; Left: Ratios in non-stimulated cells; Right: fold change of promoter activity in cells after
TNF-α (8h, 20 ng/mL) stimulus when compared with non-stimulated cells.
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